ResearcherSichuan UniversityActive in the last 2 years

Ke Cheng

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-9272-7615; OpenAlex author ID A5004340170. Sources: OpenAlex.

Their work

Papers: 3
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 14

Papers, trials and grants by year

2024: 2 papers · 2025: 1 paper

Papers 3

Continuous response to maintenance fuzuloparib for germline BRCA2- mutated metastatic pancreatic adenocarcinoma: a case report and literature review. Co-author DOI 10.3389/fphar.2025.1656670 ↗
Spatial interactions of immune cells as potential predictors to efficacy of toripalimab plus chemotherapy in locally advanced or metastatic pancreatic ductal a… Co-author DOI 10.1038/s41392-024-02031-8 ↗
Dual and triple gene combinations of KRT5, KRT17, and S100A2 identify basal-like subtype of pancreatic ductal adenocarcinoma and correlate with survival outcom… Co-author DOI 10.1096/fj.202302484rr ↗

Closest collaborators

The 14 strongest of 14 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Dan Cao · 1 shared paper, 2025 · strength 0.37
- Paper Continuous response to maintenance fuzuloparib for germline BRCA2- mutated metastatic pancreatic adenocarcinoma: a case… DOI 10.3389/fphar.2025.1656670 ↗
Chenyan Zhang · 1 shared paper, 2025 · strength 0.37
- Paper Continuous response to maintenance fuzuloparib for germline BRCA2- mutated metastatic pancreatic adenocarcinoma: a case… DOI 10.3389/fphar.2025.1656670 ↗
Qiangxing Chen · 1 shared paper, 2024 · strength 0.18
- Paper Dual and triple gene combinations of KRT5, KRT17, and S100A2 identify basal-like subtype of pancreatic ductal adenocarc… DOI 10.1096/fj.202302484rr ↗
Xin Wang · 1 shared paper, 2024 · strength 0.18
- Paper Dual and triple gene combinations of KRT5, KRT17, and S100A2 identify basal-like subtype of pancreatic ductal adenocarc… DOI 10.1096/fj.202302484rr ↗
Zhong Wu · 1 shared paper, 2024 · strength 0.18
- Paper Dual and triple gene combinations of KRT5, KRT17, and S100A2 identify basal-like subtype of pancreatic ductal adenocarc… DOI 10.1096/fj.202302484rr ↗
Bing Peng · 1 shared paper, 2024 · strength 0.18
- Paper Dual and triple gene combinations of KRT5, KRT17, and S100A2 identify basal-like subtype of pancreatic ductal adenocarc… DOI 10.1096/fj.202302484rr ↗
Heqi Yang · 1 shared paper, 2024 · strength 0.15
- Paper Spatial interactions of immune cells as potential predictors to efficacy of toripalimab plus chemotherapy in locally ad… DOI 10.1038/s41392-024-02031-8 ↗
Wanrui Lv · 1 shared paper, 2024 · strength 0.15
- Paper Spatial interactions of immune cells as potential predictors to efficacy of toripalimab plus chemotherapy in locally ad… DOI 10.1038/s41392-024-02031-8 ↗
Xiaoying Li · 1 shared paper, 2024 · strength 0.15
- Paper Spatial interactions of immune cells as potential predictors to efficacy of toripalimab plus chemotherapy in locally ad… DOI 10.1038/s41392-024-02031-8 ↗
Junjie Xiong · 1 shared paper, 2024 · strength 0.15
- Paper Spatial interactions of immune cells as potential predictors to efficacy of toripalimab plus chemotherapy in locally ad… DOI 10.1038/s41392-024-02031-8 ↗
Dan Cao · 1 shared paper, 2024 · strength 0.15
- Paper Spatial interactions of immune cells as potential predictors to efficacy of toripalimab plus chemotherapy in locally ad… DOI 10.1038/s41392-024-02031-8 ↗
Yi Cheng · 1 shared paper, 2024 · strength 0.15
- Paper Spatial interactions of immune cells as potential predictors to efficacy of toripalimab plus chemotherapy in locally ad… DOI 10.1038/s41392-024-02031-8 ↗
Rui Wang · 1 shared paper, 2024 · strength 0.15
- Paper Spatial interactions of immune cells as potential predictors to efficacy of toripalimab plus chemotherapy in locally ad… DOI 10.1038/s41392-024-02031-8 ↗
Bole Tian · 1 shared paper, 2024 · strength 0.15
- Paper Spatial interactions of immune cells as potential predictors to efficacy of toripalimab plus chemotherapy in locally ad… DOI 10.1038/s41392-024-02031-8 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.